StoneX Maintains Speculative Buy on Intensity Therapeutics, Lowers Price Target to $8
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
StoneX analyst Robert Wasserman maintains Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and lowers the price target from $12 to $8.
StoneX analyst Robert Wasserman maintains Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and lowers the price target from $12 to $8.
